Biomark Diagnostics Inc. (20B.F)

0.1590

+0.0020

+(1.27%)

At close: 3:44:28 PM GMT+2

BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test

Study Published in a special issue of International Journal of Molecular Sciences Confirms Test's Ability to Distinguish Early Lung Cancer from Other Non-Cancerous Lung Diseases Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagno

Newsfile 7 hours ago

BMKDF
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market

Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have been officially approved for uplisting from the OTC Pink Open Market to the OTCQB Venture M

Newsfile 4 days ago

BMKDF
BioMark Announces the Final Closing of Oversubscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the successful closing of its previously announced oversubscribed non-brokered private placement.The closing of the second and final tranche builds upon the momentum of the previously announced first tranche on March 26, 2025, culminating in a significantly successful f

Newsfile last month

BMKDF
BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that it has arranged and completed financing for the initial tranche of its non-brokered private placement (the "Private Placement").Demonstrating strong investor confidence in BioMark's vision and technology, BioMark secured a USD $2 million investment from a pair of strategic in

Newsfile last month

BMKDF
BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025

BioMark is pioneering liquid biopsy solutions for challenging conditions and championing equity in diagnosis Vancouver, British Columbia--(Newsfile Corp. - February 28, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, proudly joins today the global community in recognizing Rare Disease Day 2025. This annual observance, dedicated to raising awareness and support for individuals and families

Newsfile 2 months ago

BMKDF
BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction

BioMark Expands Its Liquid Biopsy Platform Receptor Status for Breast Cancer Vancouver, British Columbia--(Newsfile Corp. - December 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leader in liquid biopsy tests for early cancer detection, announced a significant advancement in its breast cancer diagnostic capabilities. A groundbreaking study published in the International Journal of Molecular Sciences (IJMS) Special Edition demonstrates the potential o

Newsfile 4 months ago

BMKDF
BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection

BioMark Strengthens Liquid Biopsy Platform for Breast Cancer Detection Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced significant progress in its breast cancer program. The Company's liquid biopsy platform, leveraging metabolomics and machine learning, is demonstrating strong potential for early detection of breast

Newsfile 6 months ago

BMKDF
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN

BioMark's Liquid Biopsy Technology Offers Promise for NEN Diagnosis Vancouver, British Columbia--(Newsfile Corp. - September 24, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is excited to announce that its latest work, has been published in Cancers, titled "Metabolic Profiling of Pulmonary Neuroendocrine Neoplasms." This paper sheds light on the metabolic alterations that define pulmonary neuroend

Newsfile 7 months ago

BMKDF
BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection

Largest Clinical Study Validating a Metabolite-based Assay for Lung Cancer Screening Vancouver, British Columbia--(Newsfile Corp. - September 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce today the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ). Over 5,400 patient sa

Newsfile 7 months ago

BMKDF
Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Vancouver, British Columbia--(Newsfile Corp. - August 26, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that Chief Executive Officer Rashid Bux and Chief Scientific Officer Jean-François Haince will participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference in New York.The Global Investment Conference will take place in person at the Lotte New York .

Newsfile 8 months ago

BMKDF
The U.S. Patent and Trademark Office Grants BioMark Patent That Expands Its Claims Covering Its Legacy Liquid Biopsy Assay

The new patent granted by the USPTO strengthens and expands BioMark's global IP portfolio in liquid biopsy, enhancing cancer management solutions. Vancouver, British Columbia--(Newsfile Corp. - July 31, 2024) - BioMark Diagnostics Inc., (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to announce the issuance of U.S. Patent No. 17/895.69 by the U.S. Patent and ...

Newsfile 9 months ago

BMKDF
Biomark Diagnostics Full Year 2024 Earnings: CA$0.017 loss per share (vs CA$0.022 loss in FY 2023)

Biomark Diagnostics ( FRA:20B ) Full Year 2024 Results Key Financial Results Revenue: CA$163.2k (up 6.3% from FY 2023...

Simply Wall St. 9 months ago

BMKDF
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research at 2024 GPEN Conference

Vancouver, British Columbia--(Newsfile Corp. - July 15, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to announce today that long time collaborators at the University of Manitoba Therapeutics will be presenting this week compelling new research findings on glioblastoma at the 2024 Globalization of Pharmaceutics Education Network (

Newsfile 9 months ago

BMKDF

Performance Overview

Return	20B.F	S&P/TSX Composite index (^GSPTSE)
YTD	+45.87%	+3.70%
1-Year	-4.22%	+14.45%
3-Year	+18.66%	+29.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TARIFFS LATEST

Biomark Diagnostics Inc. (20B.F)

BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test

BioMark Diagnostics Announces Uplisting to OTCQB Venture Market

BioMark Announces the Final Closing of Oversubscribed Private Placement

BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform

BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025

BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction

BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection

BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN

BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection

Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright's 26th Annual Global Investment Conference in New York

The U.S. Patent and Trademark Office Grants BioMark Patent That Expands Its Claims Covering Its Legacy Liquid Biopsy Assay

Biomark Diagnostics Full Year 2024 Earnings: CA$0.017 loss per share (vs CA$0.022 loss in FY 2023)

BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research at 2024 GPEN Conference

Performance Overview